Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
Globally, chronic hepatitis B (CHB) infection is one of the leading causes of liver failure, decompensated cirrhosis, and hepatocellular carcinoma. Existing antiviral therapy can suppress viral replication but not fully eradicate the virus nor the risk of liver-related complications. Novel treatment...
Main Authors: | Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/6/1169 |
Similar Items
-
Design, Synthesis, and Evaluation of a Set of Carboxylic Acid and Phosphate Prodrugs Derived from HBV Capsid Protein Allosteric Modulator NVR 3-778
by: Xiangkai Ji, et al.
Published: (2022-09-01) -
Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed
by: Ching-Lung Lai, et al.
Published: (2020-06-01) -
All-Atom MD Simulations of the HBV Capsid Complexed with AT130 Reveal Secondary and Tertiary Structural Changes and Mechanisms of Allostery
by: Carolina Pérez-Segura, et al.
Published: (2021-03-01) -
Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future
by: Mariana Daniela Ignat, et al.
Published: (2024-04-01) -
Congenital cystic adenomatoid malformation of lung in adults: 2 rare cases report and review of the literature
by: Feng Anning, et al.
Published: (2012-04-01)